UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.08 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,940 shares of the company's stock after acquiring an additional 29,262 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of Harrow worth $2,078,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of HROW. Woodmont Investment Counsel LLC increased its stake in Harrow by 0.5% in the 4th quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company's stock valued at $2,731,000 after buying an additional 445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Harrow by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock worth $582,000 after acquiring an additional 585 shares during the period. Swiss National Bank lifted its stake in Harrow by 1.0% in the 4th quarter. Swiss National Bank now owns 59,300 shares of the company's stock valued at $1,990,000 after purchasing an additional 600 shares during the last quarter. MetLife Investment Management LLC increased its position in Harrow by 5.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock valued at $634,000 after acquiring an additional 1,026 shares during the period. Finally, HighTower Advisors LLC increased its position in Harrow by 13.8% in the 4th quarter. HighTower Advisors LLC now owns 10,127 shares of the company's stock valued at $340,000 after acquiring an additional 1,227 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HROW. B. Riley cut their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. HC Wainwright lifted their target price on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th. Finally, William Blair assumed coverage on shares of Harrow in a research report on Tuesday. They set an "outperform" rating on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Harrow currently has a consensus rating of "Buy" and an average target price of $61.25.

Harrow Trading Up 1.4%

Shares of NASDAQ:HROW traded up $0.44 during mid-day trading on Wednesday, reaching $31.61. 385,419 shares of the company were exchanged, compared to its average volume of 501,331. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 1 year low of $16.87 and a 1 year high of $59.23. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -33.63 and a beta of 0.40. The firm's 50-day simple moving average is $25.84 and its 200 day simple moving average is $29.84.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The firm had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Equities research analysts forecast that Harrow, Inc. will post -0.53 EPS for the current year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.